Inovio Pharmaceuticals 過去の業績
過去 基準チェック /06
Inovio Pharmaceuticals's earnings have been declining at an average annual rate of -5.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 7% per year.
主要情報
-5.2%
収益成長率
13.8%
EPS成長率
Biotechs 業界の成長 | 11.5% |
収益成長率 | -7.0% |
株主資本利益率 | -125.7% |
ネット・マージン | -20,552.3% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
収支内訳
Inovio Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 1 | -122 | 41 | 0 |
31 Mar 24 | 1 | -125 | 45 | 0 |
31 Dec 23 | 1 | -135 | 48 | 0 |
30 Sep 23 | 1 | -165 | 37 | 0 |
30 Jun 23 | 10 | -168 | 39 | 0 |
31 Mar 23 | 10 | -241 | 73 | 0 |
31 Dec 22 | 10 | -280 | 76 | 0 |
30 Sep 22 | 11 | -332 | 90 | 0 |
30 Jun 22 | 2 | -355 | 92 | 0 |
31 Mar 22 | 2 | -328 | 56 | 0 |
31 Dec 21 | 2 | -304 | 54 | 0 |
30 Sep 21 | 7 | -221 | 48 | 0 |
30 Jun 21 | 6 | -142 | 45 | 0 |
31 Mar 21 | 6 | -188 | 44 | 0 |
31 Dec 20 | 7 | -166 | 37 | 0 |
30 Sep 20 | 2 | -180 | 37 | 0 |
30 Jun 20 | 3 | -222 | 33 | 0 |
31 Mar 20 | 3 | -123 | 28 | 0 |
31 Dec 19 | 4 | -119 | 27 | 0 |
30 Sep 19 | 6 | -115 | 24 | 0 |
30 Jun 19 | 7 | -117 | 25 | 0 |
31 Mar 19 | 32 | -94 | 27 | 0 |
31 Dec 18 | 30 | -97 | 29 | 0 |
30 Sep 18 | 37 | -86 | 32 | 0 |
30 Jun 18 | 37 | -95 | 31 | 0 |
31 Mar 18 | 33 | -97 | 30 | 0 |
31 Dec 17 | 42 | -88 | 28 | 0 |
30 Sep 17 | 42 | -93 | 27 | 0 |
30 Jun 17 | 52 | -80 | 27 | 0 |
31 Mar 17 | 38 | -89 | 26 | 0 |
31 Dec 16 | 35 | -74 | 24 | 0 |
30 Sep 16 | 33 | -65 | 22 | 0 |
30 Jun 16 | 44 | -39 | 20 | 0 |
31 Mar 16 | 44 | -27 | 19 | 0 |
31 Dec 15 | 41 | -29 | 18 | 0 |
30 Sep 15 | 37 | -19 | 17 | 0 |
30 Jun 15 | 15 | -31 | 16 | 0 |
31 Mar 15 | 13 | -36 | 16 | 0 |
31 Dec 14 | 10 | -36 | 16 | 0 |
30 Sep 14 | 10 | -44 | 16 | 0 |
30 Jun 14 | 17 | -68 | 16 | 0 |
31 Mar 14 | 14 | -68 | 15 | 0 |
31 Dec 13 | 13 | -66 | 14 | 0 |
質の高い収益: 0A43 is currently unprofitable.
利益率の向上: 0A43 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 0A43 is unprofitable, and losses have increased over the past 5 years at a rate of 5.2% per year.
成長の加速: Unable to compare 0A43's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 0A43 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
株主資本利益率
高いROE: 0A43 has a negative Return on Equity (-125.74%), as it is currently unprofitable.